tbuckley/cabot-search huggingface dataset:
Prognostic relevance of soluble vascular endothelial growth factor (VEGF), their receptors 1 (Flt-1), and placental growth factor (PLGF) in the sera of patients with pancreatic adenocarcinoma
Authors: Yu-Ting Chang, Ming-Chu Chang, Yu-Wen Tien, Shu-Chen Wei, Jau-Min Wong
Journal: Cancer Research (2007)

2691   Angiogenesis is the formation of new blood vessels and is controlled by a balance between positive and negative angiogenic regulatory factors. Vascular endothelial growth factor receptor-1 (VEGFR-1) is a member of the VEGFR family, and binds VEGF-A, placenta growth factor (PLGF), and VEGF-B. Soluble vascular endothelial growth factor receptors 1,2 (Flt-1, KDR) are the negative counterpoint to the vascular endothelial growth factor (VEGF) signaling pathway, which has been characterized as one of the most important endothelial regulator in human angiogenesis. In the present work, we tested the differential prognostic relevance of soluble vascular endothelial growth factor (VEGF), their receptors 1 (Flt-1), and placental growth factor (PLGF) in the sera of 93 patients with pancreatic adenocarcinoma and 60 healthy controls. sVEGF, PLGF and sFlt-1 were assessed using an ELISA. Serum levels of sVEGF and sFlt-1 were significant higher in patients with pancreatic adenocarcinoma compared to controls (360.88+480.973 vs 135.87+25.63 pg/ml; 52.65+19.59 vs 19.96+2.66 pg/ml;  P  P =0.001). However, there was no significant difference regarding VEGF and PLGF levels to the stage of disease ( P >0.05). Serum sFlt1 and the sVEGF/sFlt1 ratio, but not VEGF and PLGF, levels were significantly higher in those with earlier stage and better survival on univariate analysis. On multivariate analysis using the Cox proportional hazard model, sVEGF/sFlt1 ratio was the most significant predictor of overall survival of patients with pancreatic adenocarcinoma. In conclusion, sVEGF/sFlt1 ratio is an independent predictor of pancreatic adenocarcinoma patient outcome, and its significance should be assessed when considering antiangiogenic therapy. (Supported by grant NSC95-2314-B002-140)
TRAILR‐1(TNFRSF10A)のリガンド結合ドメインの683A→C多形性は結腸直腸癌生存と関連しない
Authors: Hofmann G, Langsenlehner T, Fuerst F, Gerger A, Langsenlehner U, Knechtel G, Szkandera J, Krippl P, Renner W
Journal: Annals of Oncology (2009)
Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
Authors: Joan B Soriano, Amanuel Alemu Abajobir, Kalkidan Hassen Abate, Semaw Ferede Abera, Anurag Agrawal, Muktar Beshir Ahmed, Amani Nidhal Aichour, Ibtihel Aichour, Miloud Taki Eddine Aichour, Khurshid Alam, Noore Alam, Juma M Alkaabi, Fatma Al-Maskari, Nelson Alvis-Guzman, Alemayehu Amberbir, Yaw Ampem Amoako, Mustafa Geleto Ansha, Josep M Antó, Hamid Asayesh, Tesfay Mehari Atey, Euripide Frinel G Arthur Avokpaho, Aleksandra Barac, Sanjay Basu, Neeraj Bedi, Isabela M Bensenor, Adugnaw Berhane, Addisu Shunu Beyene, Zulfiqar A Bhutta, Stan Biryukov, Dube Jara Boneya, Michael Brauer, David O Carpenter, Daniel Casey, Devasahayam Jesudas Christopher, Lalit Dandona, Rakhi Dandona, Samath D Dharmaratne, Huyen Phuc Do, Florian Fischer, Tsegaye T Gebrehiwot, Ayele Geleto, Aloke Gopal Ghoshal, Richard F Gillum, Ibrahim Abdelmageem Mohamed Ginawi, Vipin Gupta, Simon I Hay, Mohammad T Hedayati, Nobuyuki Horita, H Dean Hosgood, Mihajlo (Michael) B Jakovljevic, Spencer Lewis James, Jost B Jonas, Amir Kasaeian, Yousef Saleh Khader, Ibrahim A Khalil, Ejaz Ahmad Khan, Young-Ho Khang, Jagdish Khubchandani, Luke D Knibbs, Soewarta Kosen, Parvaiz A Koul, G Anil Kumar, Cheru Tesema Leshargie, Xiaofeng Liang, Hassan Magdy Abd El Razek, Azeem Majeed, Deborah Carvalho Malta, Treh Manhertz, Neal Marquez, Alem Mehari, George A Mensah, Ted R Miller, Karzan Abdulmuhsin Mohammad, Kedir Endris Mohammed, Shafiu Mohammed, Ali H Mokdad, Mohsen Naghavi, Cuong Tat Nguyen, Grant Nguyen, Quyen Le Nguyen, Trang Huyen Nguyen, Dina Nur Anggraini Ningrum, Vuong Minh Nong, Jennifer Ifeoma Obi, Yewande E Odeyemi, Felix Akpojene Ogbo, Eyal Oren, Mahesh PA, Eun-Kee Park, George C Patton, Katherine Paulson, Mostafa Qorbani, Reginald Quansah, Anwar Rafay, Mohammad Hifz Ur Rahman, Rajesh Kumar Rai, Salman Rawaf, Nik Reinig, Saeid Safiri, Rodrigo Sarmiento-Suarez, Benn Sartorius, Miloje Savic, Monika Sawhney, Mika Shigematsu, Mari Smith, Fentaw Tadese, George D Thurston, Roman Topor-Madry, Bach Xuan Tran, Kingsley Nnanna Ukwaja, Job F M van Boven, Vasiliy Victorovich Vlassov, Stein Emil Vollset, Xia Wan, Andrea Werdecker, Sarah Wulf Hanson, Yuichiro Yano, Hassen Hamid Yimam, Naohiro Yonemoto, Chuanhua Yu, Zoubida Zaidi, Maysaa El Sayed Zaki, Alan D Lopez, Christopher J L Murray, Theo Vos
Journal: The Lancet Respiratory Medicine (2017)

Chronic obstructive pulmonary disease (COPD) and asthma are common diseases with a heterogeneous distribution worldwide. Here, we present methods and disease and risk estimates for COPD and asthma from the Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2015 study. The GBD study provides annual updates on estimates of deaths, prevalence, and disability-adjusted life years (DALYs), a summary measure of fatal and non-fatal disease outcomes, for over 300 diseases and injuries, for 188 countries from 1990 to the most recent year.
The evolution of general intelligence in <i>all</i> animals and machines
Authors: Kay E. Holekamp, Risto Miikkulainen
Journal: Behavioral and Brain Sciences (2017)

Abstract We strongly agree that general intelligence occurs in many animals but find the cultural intelligence hypothesis of limited usefulness. Any viable hypothesis explaining the evolution of general intelligence should be able to account for it in all species where it is known to occur, and should also predict the conditions under which we can develop machines with general intelligence as well.
A practical guide to single-cell RNA-sequencing for biomedical research and clinical applications
Authors: Ashraful Haque, Jessica Engel, Sarah A. Teichmann, Tapio Lönnberg
Journal: Genome Medicine (2017)

RNA sequencing (RNA-seq) is a genomic approach for the detection and quantitative analysis of messenger RNA molecules in a biological sample and is useful for studying cellular responses. RNA-seq has fueled much discovery and innovation in medicine over recent years. For practical reasons, the technique is usually conducted on samples comprising thousands to millions of cells. However, this has hindered direct assessment of the fundamental unit of biology-the cell. Since the first single-cell RNA-sequencing (scRNA-seq) study was published in 2009, many more have been conducted, mostly by specialist laboratories with unique skills in wet-lab single-cell genomics, bioinformatics, and computation. However, with the increasing commercial availability of scRNA-seq platforms, and the rapid ongoing maturation of bioinformatics approaches, a point has been reached where any biomedical researcher or clinician can use scRNA-seq to make exciting discoveries. In this review, we present a practical guide to help researchers design their first scRNA-seq studies, including introductory information on experimental hardware, protocol choice, quality control, data analysis and biological interpretation.
糖尿病ラットの生細胞,細胞内オルガネラ,および腎組織におけるペルオキシ亜硝酸を可視化するための高速応答と高選択的蛍光プローブの新しいクラス【Powered by NICT】
Authors: Miao Junfeng, Huo Yingying, Liu Qian, Li Zhe, Shi Heping, Shi Yawei, Guo Wei
Journal: Biomaterials (2016)
Flooding in south Asia raises fear of disease outbreaks
Authors: Sophie Cousins
Journal: BMJ (2017)

Flooding has killed more than 800 people and displaced over a million in India, Nepal, and Bangladesh, raising fears of widespread outbreaks of waterborne and vectorborne disease.

Although the seasonal monsoon rains from June to September are crucial to farmers across the region, this year’s flooding has been the worst in almost a decade, affecting more than 24 million people, said the International Federation of Red Cross and Red Crescent Societies.

In the eastern Indian state of Bihar more than 250 people have lost their lives, while in the …
Alexithymia and the Split Brain
Authors: W.D. TenHouten, K.D. Hoppe, J.E. Bogen, D.O. Walter
Journal: Psychotherapy and Psychosomatics (1985)

A structural explanation of psychosomatic personality structure is proposed, that of a functional or physical deconnection of the two cerebral hemispheres. If the affective and symbolic energies of the right hemisphere cannot be externalized through verbal expressions of the left hemisphere (alexithymia), then they are apt to be directed inward, thereby contributing to psychosomatic personality structure. In an experiment, 8 cerebral commissurotomy patients and 8 precision-matched normal control subjects were shown a 3-minute videotaped film symbolically depicting the deaths of a baby and a boy. Gottschalk-Gleser content analysis of the subjects' verbal responses to the film was carried out for anxiety and hostility scales. A complex of shame and total anxiety in combination with hostility directed both inward and outward, was interpreted as an indicator of 'psychosomatic personality structure'. Cerebral commissurotomy patients showed a significantly higher level of psychosomatic personality structure than did normal controls.
OP0016 Comparative effectiveness at 1 year of different ANTI-TNF drugs as first biologic dmard in patients with rheumatoid arthritis – results from the nationwide swedish register
Authors: C Turesson, T Frisell, M Dehlin, D Di Giuseppe, N Feltelius, A Kastbom, J Askling
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Treatment with TNF inhibitors is part of the management of patients with severe rheumatoid arthritis (RA). There is limited data on the comparative effectiveness of different TNF inhibitors from clinical trials and observational studies of patients treated in clinical practice. <h3>Objectives</h3> To compare effectiveness of different TNF inhibitors in a large, population representative, sample of bionaïve patients with RA. <h3>Methods</h3> The study was based on the Swedish Rheumatology Quality register, in which clinical data are prospectively recorded at treatment initiation and at subsequent visits. Patients with RA initiating a TNF inhibitor as their first ever biologic DMARD in 2010–2014 were included and followed through 2015. The proportion remaining on drug at 1 year (±90 days) after starting therapy was compared. Furthermore, effectiveness at 1 year was assessed as the proportions with EULAR good response, remission (DAS28 &lt;2.6), HAQ improvement (&gt;0.2) and swollen and tender joint counts of 0, all corrected for drug survival (1). The relative response was estimated with log-binomial regression, adjusting for potential confounders and using the largest group (etanercept) as reference. <h3>Results</h3> A total of 5568 patients were included. There was a significant difference in the adjusted chance of drug survival across TNF inhibitors (Table). Patients treated with certolizumab or infliximab were less likely to remain on treatment compared to those started on etanercept. The chance of achieving each of the clinical response measures was significantly lower for those initiating infliximab compared to patients treated with etanercept. There were no significant differences in these outcomes compared to etanercept for any of the other TNF inhibitors. <h3>Conclusions</h3> Patients with RA starting infliximab as their first biologic DMARD were less likely to remain on treatment with significant improvement at 1 year compared to those initiating etanercept. There was a similar trend for certolizumab vs. etanercept, but there were no consistent differences in clinical effectiveness between etanercept and adalimumab or golimumab. Treatment context may affect these patterns. <h3>References</h3> Kristensen A&amp;R 2006; 54: 600–6. <h3>Disclosure of Interest</h3> C. Turesson Grant/research support from: Abbvie, Pfizer, Roche, Consultant for: MSD, Pfizer, Roche, Paid instructor for: Abbvie, Bristol-Myers Squibb, Janssen, MSD, Pfizer, Roche and UCB, T. Frisell: None declared, M. Dehlin: None declared, D. Di Giuseppe: None declared, N. Feltelius: None declared, A. Kastbom Consultant for: Bristol-Myers Squibb, Pfizer, Roche, UCB, Paid instructor for: Bristol-Myers Squibb, Pfizer, Roche, UCB, J. Askling Grant/research support from: Abbvie, UCB, Pfizer, Merck, Samsung, Roche, Lilly
Long-Term Incremental Prognostic Value of Cardiovascular Magnetic Resonance After ST-Segment Elevation Myocardial Infarction
Authors: Rolf Symons, Gianluca Pontone, Juerg Schwitter, Marco Francone, Juan Fernando Iglesias, Andrea Barison, Jaroslaw Zalewski, Laura de Luca, Sophie Degrauwe, Piet Claus, Marco Guglielmo, Jadwiga Nessler, Iacopo Carbone, Giovanni Ferro, Monika Durak, Paolo Magistrelli, Alfonso Lo Presti, Giovanni Donato Aquaro, Eric Eeckhout, Christian Roguelov, Daniele Andreini, Pierre Vogt, Andrea Igoren Guaricci, Saima Mushtaq, Valentina Lorenzoni, Olivier Muller, Walter Desmet, Luciano Agati, Stefan Janssens, Jan Bogaert, Pier Giorgio Masci
Journal: JACC. Cardiovascular imaging (2017)
Peripheral Artery Disease in Japanese Patients Undergoing Percutaneous Coronary Intervention: Multicenter Registry of Kumamoto Intervention Conference Study (KICS)
Authors: Ogawa Shimpei, Hokimoto Seiji, Akasaka Tomonori, Ohshima Shuichi, Nakao Koichi, Shimomura Hideki, Fujimoto Kazuteru, Imanaka Yuichi, Ogawa Hisao
Journal: Circulation (2015)
Abstract 117: Heparin Derived Oligosaccharide Inhibits Vascular Intimal Hyperplasia in Balloon Injured Carotid Artery and the Mechanism Involved
Authors: He Shuying, Wu Jie
Journal: Circulation Research (2015)

To determine the effects of heparin-derived oligosaccharides (HDOs) on vascular intimal hyperplasia (IH) in balloon-injured carotid artery and the mechanism involved. The animal model was established by rubbing the endothelia within the common carotid artery (CCA) of male rabbits along with a high-cholesterol diet. The arterial IH was testified by histopathological changes of the CCA. Serum lipids were detected using automated biochemical analysis; Expression of mRNAs corresponding to vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular cell adhesion molecule-1 (VCAM-1), monocyte chemoattractant protein-1 (MCP-1), scavenger receptor class B type I (SR-BI) and ATP-binding cassette transporter A1 (ABCA-1) were analyzed using reverse transcription polymerase chain reaction assays. Expressions of VEGF, VCAM-1, MCP-1, SR-BI and ABCA-1 proteins were detected by western blotting. Enzyme-linked immunosorbent assays were used to quantify expression levels of VEGF and bFGF. The results implied that administration of HDO significantly inhibited common carotid artery histopathology and restenosis that was induced by balloon injury. Treatment with HDO also significantly decreased mRNA and protein expression levels of VEGF, bFGF, VCAM-1, MCP-1, and SR-BI in the arterial wall, however ABCA-1 expression levels were elevated. HDO treatment led to a reduction in various serum lipids (total cholesterol, triglycerides, high-density and low-density lipoproteins). We concluded that, in a rabbit model, HDO can ameliorate IH and the mechanisms might involved VEGF, bFGF, VCAM-1, MCP-1, SR-BI and ABCA-1.
Clinical Factors Predicting Better Survival Outcome for Pulmonary Metastasectomy of Hepatocellular Carcinoma
Authors: Tse-Ming Kuo, Kai-Ming Chang, Tsun-I Cheng, Kuo-Jang Kao
Journal: Liver Cancer (2017)

In patients with lung metastasis of hepatocellular carcinoma (HCC), it remains uncertain how a better survival outcome can be predicted after metastasectomy. This study aims to identify clinical factors that may be used to guide patient selection for such a therapeutic modality. A total of 28 patients who received pulmonary metastasectomy for HCC between 1993 and 2012 were identified. All relevant clinical factors were extracted from medical records up to September 2015. Patients were classified into high- and low-risk groups according to survival outcome after metastasectomy. All pertinent clinical factors were analyzed for correlation with survival outcome.The overall survival of 28 patients after pulmonary metastasectomy was studied first. The survival curve was biphasic and reached a plateau at 40 months after metastasectomy. The results indicate the presence of 2 groups of patients with a different survival outcome. Among all clinical parameters, remission status in the liver before pulmonary metastasectomy and distant metastasis-free interval between the last treatment of HCC and the occurrence of lung metastasis were found to be significantly associated with excellent survival outcome after pulmonary metastasectomy (p = 0.019 and 0.007 by Fisher exact test, and p = 0.002 and 0.0002 by Cox regression analysis).
癌免疫療法のための抗原ペプチドnanovaccineによるリンパ節における樹状細胞の標的化【Powered by NICT】
Authors: Qian Yuan, Jin Honglin, Qiao Sha, Dai Yanfeng, Huang Chuan, Lu Lisen, Luo Qingming, Zhang Zhihong
Journal: Biomaterials (2016)
Multicenter randomized phase III trial of 3-weekly paclitaxel/platinum (PC3w) versus weekly paclitaxel/platinum (PCw) induction therapy followed by PC3w maintenance therapy in advanced epithelial ovarian cancer (EOC)
Authors: M. E. Burg, J. T. Janssen, P. B. Ottevanger, L. G. Kerkhofs, F. Valster, J. M. Stouthard, W. Onstenk, F. Termorshuizen, J. Verweij
Journal: Journal of Clinical Oncology (2009)

5538 Background: Response rates (RR) up to 50% were found with PCw in platinum resistant EOC. We compared the efficacy of first-line PCw induction therapy to PC3w. Methods: 270 patients (pts) with FIGO stage II-IV, Performance status (PS) 0–2 were randomly assigned to 3 x PC3w (P 175mg/m2 with either cisplatin [Cis] 75mg/m 2 or carboplatin [Car] AUC 6) or 6 x PCw (P 90mg/m2 with either Cis 70mg/m 2 or Car AUC 4, day 1,8,15 and day 29,36,43) followed by up to 6 cycles PC3w in both arms. Pts were stratified for FIGO stage, PS, tumor size and center. Primary endpoints were progression free survival (PFS) and overall survival (OS). Secondary endpoints were RR and toxicity. A total of 225 events were needed to detect a 10–13% absolute difference in PFS/OS with a power of 84% (one-sided). Results: 267 pts (134 TC-3w and 133 TCw) were eligible (3 pts wrong tumor type). Pt characteristics were well balanced; median age 58 years, serous 62%, residual disease &gt;1cm 66%, FIGO stage II 7%, III 64%, IV 29%. Median dose-intensity for PC3w was: P 58(47–58) and Cis 25(22.5–25) mg/m 2 /w, Car 2(1.6–2) AUC/w, for PCw: P 60(36–60) and Cis 44.7(30–44.7) mg/m 2 /w and for Car 2.7(1,6–2,7) AUC/w. After a median follow-up of 39 months (m) (range 0.03 - 93.3m) 206 pts (77%) had progressed and 164 pts (61%) had died. Median PFS was 18m for TC3w and 19m for TCw, 5-year PFS was 20% and 18%, respectively (logrank test: p = 0.63). Median OS was 44m for TC3w and 45m for TCw, 5-year OS was 36% and 37%, respectively (logrank test: p = 0.87). RR after induction therapy in 176 pts with measurable disease was 72% for TC3w and 74% for TCw (p = 0.68). TCw was well tolerated. Grade 3/4 toxicity for TC3w vs. TCw was respectively, platelets 1.75% vs.1.55% (ns), WBC 5.5% vs. 8.7 (p = &lt;0.0001), granulocytes 16.7% vs. 11.7% (p = &lt;0.001) and delay 3% vs. 9% of the cycles. TCw induced less grade 2/3 muscular and joint pain (TC3w 6.3% and 3.5% vs. TCw 0.3% and 0.8% of the cycles) and less neurotoxicity (TC3w 6% vs. 1.6% of the pts in TCw). The other toxicities were similar in frequency and severity in both arms. Conclusions: TCw was well tolerated and had less granulocytopenia, neurotoxicity, and muscular and joint pain but did not yield benefit in terms of OS, PFS or RR. No significant financial relationships to disclose.
Suppression of cigarette smoke condensate-induced NFκB activation in normal human bronchial cells by green tea polyphenol EGCG
Authors: Deeba N. Syed, Farrukh Afaq, Mee-Hyang Kweon, Naghma Hadi, Neehar Bhatia, Vladimir S. Spiegelman, Hasan Mukhtar
Journal: Cancer Research (2006)

2256   Exposure to environmental tobacco smoke is associated with an increased risk of lung cancer, currently responsible for one third of cancer deaths in many Western countries. There is considerable evidence from various mammalian cell culture studies and animal models, that (-)-epigallocatechin-3-gallate (EGCG), the major polyphenol present in green tea, possesses potent anti-inflammatory and antiproliferative activity capable of selectively inhibiting cell growth and inducing apoptosis in cancer cells without adversely affecting normal cells. Cigarette smoke is a powerful inducer of inflammatory responses resulting in disruption of major cellular pathways with transcriptional and genomic alterations driving the cells towards carcinogenesis. Green tea consumption has been reported to inhibit cigarette smoke-induced mutations in humans. Here, we demonstrate that EGCG pretreatment (20-80μM) of normal human bronchial epithelial cells (NHBE) resulted in significant inhibition of cigarette smoke condensate (CSC)-induced cell proliferation. Nuclear factor kappa B (NFκB) controls the transcription of genes involved in immune and inflammatory responses. In most cells NFκB prevents apoptosis by mediating cell signal survivals. We therefore examined the effect of EGCG on CSC-induced activation of NFκB in NHBE cells. Western blot analysis showed that pretreatment of NHBE cells with EGCG effectively suppressed CSC-induced phosphorylation and degradation of IκBα, and activation of NFκB. Inhibition of CSC-mediated nuclear translocation and DNA binding of p65 (RelA) in EGCG pretreated cells was further demonstrated using immunocytochemistry and ELISA. NHBE cells transfected with a luciferase reporter plasmid containing an NFκB-inducible promoter sequence showed an increased reporter activity after CSC exposure that was specifically inhibited by EGCG pretreatment. Immunoblot analysis further showed that pretreatment of NHBE cells with EGCG resulted in a significant down regulation of NFκB-regulated proteins involved in the process of tumorigenesis including cyclin D1, iNOS, and MMP-9. Mitogen-activated Protein Kinases (MAPKs) involved in the cellular stress response through regulation of transcriptional factors play a key role in cell growth, differentiation and apoptosis. Immunoblot analysis revealed that CSC-induced phosphorylation of MAPKs was inhibited by EGCG in a dose dependent manner. Taken together, our data indicates that EGCG can suppress NFκB activation in NHBE cells, which may contribute to its ability to suppress inflammation, proliferation, and angiogenesis induced by cigarette smoke. Further understanding of its molecular mechanism of action may have important implications for developing novel chemopreventive regimens that can afford protection against lung cancer in smokers as well as those exposed to secondhand smoke.
Evolution of the degradation mechanism of pure zinc stent in the one-year study of rabbit abdominal aorta model
Authors: Hongtao Yang, Cong Wang, Chaoqiang Liu, Houwen Chen, Yifan Wu, Jintao Han, Zichang Jia, Wenjiao Lin, Deyuan Zhang, Wenting Li, Wei Yuan, Hui Guo, Huafang Li, Guangxin Yang, Deling Kong, Donghui Zhu, Kazuki Takashima, Liqun Ruan, Jianfeng Nie, Xuan Li, Yufeng Zheng
Journal: Biomaterials (2017)